Treatments blocking the synthesis of TGF-β and TGF-β receptor 1 kinase inhibitors have shown promise in high-grade gliomas, while a small molecule TGF-β1 inhibitor is demonstrating promising efficacy in the treatment of HCC (87, 88). Here, TGFB1 is linked to hepatocellular carcinoma.